| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | 2026-07-30 | 6/12 | 2 high, 4 medium, 1 low flags | 2 | 1 | Call sheet → |
| Q1'26 | April 30, 2026 | 9/12 | 1 high, 3 medium, 2 low flags | 1 | 1 | Call sheet → |
| Q4'25 | 2026-01-29 | 11/12 | 2 medium, 5 low flags | 5 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Pending | SmartCare business unit to drive growth Kevin says 'expecting a very strong second half' but no metrics provided |
| Q2'26 | Delivered | Full year guidance 8%-9.5% maintained Narrowed to 8.3%-9.3%, raised floor but cut ceiling |
| Q2'26 | Missed | Peripheral vascular 'clear sailing in years ahead' Supply disruption created meaningful backorder and lost sales |
| Q2'26 | Pending | Rescheduling procedures into Q3/Q4 Capital backlog elevated but no clarity on procedure reschedule status |
| Q2'26 | Delivered | Catch up of revenue recognition in Q2 9% organic growth shows clear recovery from 2.4% in Q1 |
| Q2'26 | Pending | Most of Q1 lost sales to be realized throughout rest of year Q2 showed recovery but Preston now says 'hard to pin down' what's catch-up versus underlying |
| Q1'26 | Delivered | Active in M&A with strong balance sheet Announced Amplitude Vascular acquisition as promised |
| Q1'26 | Missed | Continued focus on operational excellence and margin expansion Operating margin fell 180 bps - though cyber incident provides excuse |
| Q1'26 | Pending | Supply constraints from 2025 will not impact 2026 growth Can't assess yet but cyber incident created new supply issues |
| Q1'26 | Pending | Mako shoulder launching on Mako 4 mid-year Reconfirmed timeline from Q4 - specific commitment to watch |
| Q1'26 | Pending | International markets represent significant growth opportunities International grew 3.9% vs 7.5% full year 2025 - trend is decelerating not accelerating |
| Q1'26 | Pending | Full year 2026 organic growth 8-9.5% and EPS $14.90-15.10 Made this promise in Q4, maintained it despite Q1 disaster - massive commitment that requires strong recovery |
| Q4'25 | Exceeded | Continue Mako installation momentum Record Q4 both U.S. and worldwide, passed 3,000 installed base milestone |
| Q4'25 | Delivered | LIFEPAK 35 launch in Europe Launched at end of Q3, now contributing to Q4 Medical performance |
| Q4'25 | Delivered | Strong Q4 finish with momentum 11% Q4 organic growth vs 9.5% Q3, raised full-year guidance |
| Q4'25 | Exceeded | Second consecutive year of 100+ bps operating margin expansion Delivered 100+ bps expansion while absorbing $200M tariff impact |
| Q4'25 | Delivered | Inari double-digit pro forma growth in 2025 Confirmed on track with ~$590M sales for 10 months as part of Stryker |
| Q4'25 | Pending | Medical to achieve 10% organic sales growth in 2025 despite supply disruptions Not explicitly confirmed in Q4 but said supply issues won't impact 2026 - implies 2025 target met |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.